Shopping Cart 0
Cart Subtotal
USD 0

Akari Therapeutics Plc (AKTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a and formation of C5b-9. The company's pipeline products include paroxysmal nocturnal hemoglobinuria, Guillain Barre Syndrome and atypical hemolytic uremic syndrome. Akari pipeline products include Coversin, Coversin LA, LTB4+C5, LTB4, LTBA LA, and bioamine inhibitors. The company operates in Switzerland, Israel, the UK and the US. Akari is headquartered in New York City, New York, the US.

Akari Therapeutics Plc (AKTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11

Licensing Agreements 12

Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12

Equity Offering 13

Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13

Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15

Celsus Therapeutics Completes Public Offering Of American Depositary Shares For USD 8 Million 17

Celsus Therapeutics Completes Private Placement Of Shares For USD 12.5 Million 19

Morria Biopharma Completes Private Placement Of Shares For USD 0.8 Million 20

Morria Biopharma Completes Private Placement Of Units For USD 1.5 Million 21

Acquisition 22

Celsus Therapeutics Acquires Volution Immuno Pharma 22

Akari Therapeutics Plc-Key Competitors 23

Akari Therapeutics Plc-Key Employees 24

Akari Therapeutics Plc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Sep 27, 2018: Akari announces second quarter 2018 financial results and business highlights 26

Aug 17, 2018: Akari announces first quarter 2018 financial results and update on its growing pipeline of phase II and phase III clinical trials 27

Mar 21, 2018: Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress 29

Corporate Communications 31

May 08, 2018: Akari Therapeutics: Resignation of CEO 31

Jan 23, 2018: Akari Therapeutics Strengthens Board with Two Senior Industry Appointments 32

Aug 21, 2017: Akari Therapeutics Announces Appointment of David Horn Solomon as CEO 33

May 30, 2017: Akari Therapeutics Announces Resignation of CEO 34

Product Approvals 35

Mar 30, 2017: Akari Therapeutics Announces FDA Fast Track Designation For Coversin 35

Clinical Trials 36

Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association 36

Feb 06, 2018: Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials 37

Dec 08, 2017: Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint 38

Oct 11, 2017: Akari Therapeutics Announces Further Clinical Progress 39

Sep 21, 2017: Akari Therapeutics Announces Regulatory Progress Following FDA Meeting 40

Apr 27, 2017: Akari Therapeutics Announces Edisons Withdrawal of Edison Report titled Akari's Coversin matches Soliris in Phase II 41

Apr 24, 2017: Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets 42

Jan 03, 2017: Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akari Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11

Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12

Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13

Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15

Celsus Therapeutics Completes Public Offering Of American Depositary Shares For USD 8 Million 17

Celsus Therapeutics Completes Private Placement Of Shares For USD 12.5 Million 19

Morria Biopharma Completes Private Placement Of Shares For USD 0.8 Million 20

Morria Biopharma Completes Private Placement Of Units For USD 1.5 Million 21

Celsus Therapeutics Acquires Volution Immuno Pharma 22

Akari Therapeutics Plc, Key Competitors 23

Akari Therapeutics Plc, Key Employees 24

Akari Therapeutics Plc, Other Locations 25

Akari Therapeutics Plc, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Akari Therapeutics Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a and formation of C5b-9. The company's pipeline products include paroxysmal nocturnal hemoglobinuria, Guillain Barre Syndrome and atypical hemolytic uremic syndrome. Akari pipeline products include Coversin, Coversin LA, LTB4+C5, LTB4, LTBA LA, and bioamine inhibitors. The company operates in Switzerland, Israel, the UK and the US. Akari is headquartered in New York City, New York, the US.

Akari Therapeutics Plc (AKTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11

Licensing Agreements 12

Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12

Equity Offering 13

Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13

Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15

Celsus Therapeutics Completes Public Offering Of American Depositary Shares For USD 8 Million 17

Celsus Therapeutics Completes Private Placement Of Shares For USD 12.5 Million 19

Morria Biopharma Completes Private Placement Of Shares For USD 0.8 Million 20

Morria Biopharma Completes Private Placement Of Units For USD 1.5 Million 21

Acquisition 22

Celsus Therapeutics Acquires Volution Immuno Pharma 22

Akari Therapeutics Plc-Key Competitors 23

Akari Therapeutics Plc-Key Employees 24

Akari Therapeutics Plc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Sep 27, 2018: Akari announces second quarter 2018 financial results and business highlights 26

Aug 17, 2018: Akari announces first quarter 2018 financial results and update on its growing pipeline of phase II and phase III clinical trials 27

Mar 21, 2018: Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress 29

Corporate Communications 31

May 08, 2018: Akari Therapeutics: Resignation of CEO 31

Jan 23, 2018: Akari Therapeutics Strengthens Board with Two Senior Industry Appointments 32

Aug 21, 2017: Akari Therapeutics Announces Appointment of David Horn Solomon as CEO 33

May 30, 2017: Akari Therapeutics Announces Resignation of CEO 34

Product Approvals 35

Mar 30, 2017: Akari Therapeutics Announces FDA Fast Track Designation For Coversin 35

Clinical Trials 36

Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association 36

Feb 06, 2018: Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials 37

Dec 08, 2017: Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint 38

Oct 11, 2017: Akari Therapeutics Announces Further Clinical Progress 39

Sep 21, 2017: Akari Therapeutics Announces Regulatory Progress Following FDA Meeting 40

Apr 27, 2017: Akari Therapeutics Announces Edisons Withdrawal of Edison Report titled Akari's Coversin matches Soliris in Phase II 41

Apr 24, 2017: Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets 42

Jan 03, 2017: Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akari Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11

Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12

Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13

Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15

Celsus Therapeutics Completes Public Offering Of American Depositary Shares For USD 8 Million 17

Celsus Therapeutics Completes Private Placement Of Shares For USD 12.5 Million 19

Morria Biopharma Completes Private Placement Of Shares For USD 0.8 Million 20

Morria Biopharma Completes Private Placement Of Units For USD 1.5 Million 21

Celsus Therapeutics Acquires Volution Immuno Pharma 22

Akari Therapeutics Plc, Key Competitors 23

Akari Therapeutics Plc, Key Employees 24

Akari Therapeutics Plc, Other Locations 25

Akari Therapeutics Plc, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Akari Therapeutics Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.